Key facts
Nok Therapeutics, Inc.
New Form D on file · 2026-03-26 · the record
What the record says
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $1K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
On the filing as: Executive Officer, Director, Promoter.
Robert Lewis is named as No family relationship with Martin Lewis or Michael Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
Brian Cogley is named as Executive Officer and Director on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
Bruce Cassidy is named as Director on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
On the filing as: Director.
Martin Lewis is named as No family relationship with Michael Lewis or Robert Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
On the filing as: Promoter.
Michael Lewis is named as No family relationship with Martin Lewis or Robert Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
David Mehalick is named as Promoter on the Form D that Nok Therapeutics, Inc. filed with the SEC on 26 March 2026, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role, 2 as directors only and 2 named in another capacity.
Named as of the 2026-03-26 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 6 people named on the filing — 2 holding an executive role, 2 as directors only and 2 named in another capacity.
No investor is drawn from a Form D — the form states how many invested and never who.
Want the whole picture on Nok Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nok Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nok Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Nok Therapeutics, Inc.
- Source Check — verify Robert Lewis's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Robert Lewis for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Nok Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Nok Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.